Stay updated on Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.

Latest updates to the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page
- Check3 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a new version of the page/documentation has been published. This appears to be a minor, behind-the-scenes update rather than a substantive change to the study details or user-facing content.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedTaiwan site listing now specifies Taoyuan City rather than Taoyuan, clarifying the exact location.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision: v3.5.3 now appears, replacing Revision: v3.5.2. This indicates a version update to the page’s documentation or release notes rather than changes to study data or core content.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page’s software/site revision indicator was updated from v3.5.0 to v3.5.2, with no visible changes to the study information.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing the previous revision v3.4.3.SummaryDifference0.0%

- Check76 days agoChange DetectedThe revision tag was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.